



(43) International Publication Date
15 November 2012 (15.11.2012)

WIPO | PCT

(10) International Publication Number
WO 2012/154812 A1

(51) International Patent Classification:

C07D 409/10 (2006.01) *C07H 7/04* (2006.01)
A61K 31/70 (2006.01)

(21) International Application Number:

PCT/US2012/037062

(22) International Filing Date:

9 May 2012 (09.05.2012)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/483,887 9 May 2011 (09.05.2011) US

(71) Applicant (for all designated States except US):

JANSSEN PHARMACEUTICA NV [BE/BE]; Turnhout-
seweg 30, B-2340 Beerse (BE).

(72) Inventors; and

(75) Inventors/Applicants (for US only): NGUYEN, Minh
[US/US]; 18 Bearse Avenue, Apt. 3, Dorchester, MA
02124 (US). COLLIER, Edwin, A. [GB/US]; C/o Janssen
Research & Development, Llc, 1000 Route 202, Raritan,
NJ 08669 (US).

(74) Agents: JOHNSON, Philip S. et al.; Johnson & Johnson,
One Johnson & Johnson Plaza, New Brunswick, NJ 08933
(US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,

AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR,
KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME,
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,
OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD,
SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR,
TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to the identity of the inventor (Rule 4.17(i))
- as to applicant's entitlement to apply for and be granted a
patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the
earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))

(54) Title: L-PROLINE AND CITRIC ACID CO-CRYSTALS OF (2S, 3R, 4R, 5S, 6R)- 2- (3- ((5- (4-
FLUOROPHENYL)THIOPHEN-2-YL) METHYL) -4-METHYLPHENYL)-6- (HYDROXYMETHYL)TETRAHYDRO-2H-
PYRAN-3,4,5-TRIOL

(57) Abstract: The present invention is directed to L-proline and citric acid co-crystals of (2S,3R,4R,5S,6R)-2-(3-((5-(4-fluorophenyl)thiophen-2-yl)methyl)-4-methylphenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol, pharmaceutical compositions containing said co-crystals and their use in the treatment glucose-related disorders such as Type 2 diabetes mellitus and Syndrome X.



WO 2012/154812 A1